hotspot -WSS

hotspot

author：focus 2025-10-01 12:12:11 - browse：98622

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： IVF doctors demand details after CooperSurgical lawsuit

focus

WSS

Medicare Advantage insurers face 0.2% cut to 2025 payments

Pancreatic cancer early detection could be helped by AI

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Ozempic has benefits for kidney disease as well as diabetes

Ozempic has benefits for kidney disease as well as diabetes

Merck, Johnson & Johnson CEOs will testify on high drug prices

entertainment

hotspot

knowledge

Heart attack and stroke risk calculators need revising

Harvard's David Sinclair gets blowback over aging

Supreme Court strikes down use of affirmative action

Biden's 'march

Dobbs anniversary: the lost opportunity of abortion as health care

IVF doctors demand details after CooperSurgical lawsuit

Hollywood unions extend contract negotiations for actors

Bernie Sanders is gearing up to subpoena pharma CEOs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

He's 19 months old and has one of the world’s rarest diseases

hotspot

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

White House pharmacy plagued with problems, investigation finds

10 reasons why health care startups fail

Medicare Advantage insurers face 0.2% cut to 2025 payments

Bernie Sanders is gearing up to subpoena pharma CEOs

knowledge

focus

hotspot

explore